Administration of nonviral gene vector encoding rat β-defensin-2 ameliorates chronic Pseudomonas aeruginosa lung infection in rats

Journal of Gene Medicine

Volumn 12, Issue 3, 2010, Pages 276-286

  Hu, Qiongjie ^a   Zuo, Peng ^a   Shao, Bing ^a   Yang, Shuo ^a   Xu, Guopeng ^a   Lan, Fen ^a   Lu, Xiaoxia ^a   Xiong, Weining ^a   Xu, Yongjian ^a   Xiong, Shengdao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

defensin 2; Bacterial infection; Gene transfer; Host defense peptides; Innate immunity; Pseudomonas aeruginosa

Indexed keywords

BETA DEFENSIN 2; INTERLEUKIN 1BETA; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; PLASMID DNA; PLASMID VECTOR; POLYETHYLENEIMINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHO CELL; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; INNATE IMMUNITY; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSGENE;

ANIMALS; BETA-DEFENSINS; CHEMOKINES; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA; RATTUS;

EID: 77349103674     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1435     Document Type: Article

References (58)

1. Rello J, Diaz E. Pneumonia in the intensive care unit. Crit Care Med 2003; 31: 2544-2551.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
3. Chastre J, Trouillet JL. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect 2000; 15: 287-298.
4. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the pulmonary complications, ICU support, and prognostic factors of hospitalized patients with HIV (PIP) study. Chest 2000; 117: 1017-1022.
5. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853-860.
6. Kukavica-Ibrulj I, Levesque RC. Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. Lab Anim 2008; 42: 389-412.
7. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30: 131-141.
8. Doss M, White MR, Tecle T, Hartshom KL. Humandefensins and LL-37 in mucosal immunity. J Leukoc Biol 2010; 87(1): 79-92.
9. Varoga D, Pufe T, Harder J, et al. Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis Rheum 2005; 52: 1736-1745.
10. Varoga D, Paulsen FP, Kohrs S, et al. Expression and regulation of human beta-defensin-2 in osteoarthritic cartilage. J Pathol 2006; 209: 166-173.
11. Diamond G, Kaiser V, Rhodes J, Russell JP, Bevins CL. Transcription regulation of beta-defensin gene expression in tracheal epithetial cells. Infect Immun 2000; 68: 113-119.
12. Harder J, Meyer-Hoffert U, Teran LM, et al. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1 beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000; 22: 714-721.
13. Tsutsumi-Ishii Y, Nagaoka I. Modulation of human betadefensin-2 transcription in pulmonary epithelial cells by lipopolysaccharide-stimulated mononuclear phagocytes via proinflammatory cytokine production. J Immunol 2003; 170: 4226-4236.
14. Hiratsuka T, Nakazato M, Date Y, et al. Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. Biochem Biophys Res Commun 1998; 249: 943-947.
15. Kolls JK, McCray PB Jr, Chan YR. Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol 2008; 8: 829-835.
16. Paulsen F, Pufe T, Conradi L, et al. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J Pathol 2002; 198: 369-377.
17. Varoga D, Klostermeier E, Paulsen F, et al. The antimicrobial peptide HBD-2 and the Toll-like receptors-2 and -4 are induced in synovial membranes in case of septic arthritis. Virchows Arch 2009; 454: 685-694.
18. Varoga D, Pufe T, Harder J, et al. Production of endogenous antibiotics in articular cartilage. Arthritis Rheum 2004; 50: 3526-3534.
19. Varoga D, Tohidnezhad M, Paulsen F, et al. The role of human beta-defensin-2 in bone. J Anat 2008; 213: 749-757.
20. Hao HN, Zhao J, Lotoczky G, Grever WE, Lyman WD. Induction of human beta-defensin-2 expression in human astrocytes by lipopolysaccharide and cytokines. J Neurochem 2001; 77: 1027-1035.
21. Brandenburg LO, Varoga D, Nicolaeva N, et al. Role of glial cells in the functional expression of LL-37/rat cathelin-related antimicrobial peptide in meningitis. J Neuropathol Exp Neurol 2008; 67: 1041-1054.
22. Brandenburg LO, Varoga D, Nicolaeva N, et al. Expression and regulation of antimicrobial peptide rCRAMP after bacterial infection in primary rat meningeal cells. J Neuroimmunol 2009; 217: 55-64.
23. Singh PK, Jia HP, Wiles K, et al. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998; 95: 14961-14966.
24. Chen CI, Schaller-Bals S, Paul KP, Wahn U, Bals R. Betadefensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cyst Fibros 2004; 3: 45-50.
25. Tsutsumi-Ishii Y, Nagaoka I. NF-kappa B-mediated transcriptional regulation of human beta-defensin-2 gene following lipopolysaccharide stimulation. J Leukocyte Biol 2002; 71: 154-162.
26. Shu Q, Shi Z, Zhao Z, et al. Protection against Pseudomonas aeruginosa pneumonia and sepsis-induced lung injury by overexpression of beta-defensin-2 in rats. Shock 2006; 26: 365-71.
27. Waqner JG, Roth RA. Neutrophil migrationmechanisms, with an emphasis on the pulmonary vasculature. Pharmacol Rev 2000; 52: 349-374.
28. Courtney JM, Ennis M, Elborn JS. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros 2004; 3: 223-231.
29. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32: 277-287.
30. Schuster A, Haarmann A, Wahn V. Cytokines in neutrophildominated airway inflammation in patients with cystic fibrosis. Eur Arch Otorhinolaryngol 1995; 252(Suppl 1): S59-S60.
31. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-1029.
32. Niyonsaba F, Oqawa H, Naqaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factoralpha-treated human neutrophils. Immunology 2004; 11: 273-281.
33. Kawai T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide- inducible genes. J Immunol 2001; 167: 5887-5894.
34. Liu H, Liu L, Fletcher BS, Visner GA. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med 2006; 173: 566-572.
35. Johansen HK, Espersen F, Pedersen SS, Hougen HP, Rygaard J, Høiby N. Chronic Pseudomonas aeruginosa lung infection in normal and athymic rats. APMIS 1993; 101: 207-225.
36. Liu L, Sanz S, Heggestad AD, Antharam V, Notterpek L, Fletcher BS. Endothelial targeting of the sleeping beauty transposon within lung. Mol Ther 2004; 10: 97-105.
37. Stover CK, Pham XQ, Erwin AC, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959-964.
38. Pedersen SS, Shand GH, Hansen BL, Hansen GN. Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS 1990; 98: 203-211.
39. Wu H, Song Z, Givskov M, et al. Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology 2001; 147: 1105-1113.
40. Johansen HK, Espersen F, Cryz SJ Jr, et al. Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun 1994; 62: 3146-3155.
41. Song Z, Kharazmi A, Wu H, et al. Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia. Clin Diagn Lab Immunol 1998; 5: 882-887.
42. Song Z, Wu H, Mygind P, et al. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother 2005; 49: 3868-3874.
43. Schneider T, Issekutz AC. Quantitation of eosinophil and neutrophil infiltration into rat lung by specific assays for eosinophil peroxidase and myeloperoxidase application in a brown norway rat model of allergic pulmonary inflammation. J Immunol Methods 1996; 198: 1-14.
44. Ouhara K, Komatsuzawa H, Yamada S, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55: 888-896.
45. Mookherjee N, Hancock RE. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 2007; 64: 922-33.
46. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006; 18: 24-30.
47. Bonnet ME, Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 2008; 25: 2972-2982.
48. Ferrari S, Pettenazzo A, Garbati N, Zacchello F, Behr JP, Scarpa M. Polyethylenimine shows properties of interest for cystic fibrosis gene therapy. Biochim Biophys Acta 1999; 1447: 219-225.
49. Bals R, Goldman MJ, Wilson JM. Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun 1998; 66: 1225-1232.
50. Morrison GM, Davidson DJ, Dorin JR. A novel mouse beta defensin, Defb2, which is upregulated in the airways by lipopolysaccharide. FEBS Lett 1999; 442: 112-116.
51. Hölzl MA, Hofer J, Steinberger P, Pfistershammer K, Zlabinger GJ. Host antimicrobial proteins as endogenous immunomodulators. Immunol Lett 2008; 119: 4-11.
52. Reiniger N, Lee MM, Coleman FT, Ray C, Golan DE, Pier GB. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulatormodulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect Immun 2007; 75: 1598-1608.
53. Vora P, Youdim A, Thomas LS, et al. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 2004; 173: 5398-5405.
54. Wu M, McClellan SA, Barrett RP, Hazlett LD. Beta-defensin-2 promotes resistance against infection with P aeruginosa. J Immunol 2009; 182: 1609-1616.
55. Mizgerd JP. Molecular mechanisms of neutrophil recruitment elicited by bacteria in the lungs. Semin Immunol 2002; 14: 123-132.
56. Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 2000; 68: 4289-4296.
57. Rovai LE, Herschman HR, Smith JB. The murine neutrophilchemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue-specific sensitivities to glucocor-ticoid regulation in endotoxemia. J Leukoc Biol 1998; 64: 494-502.
58. Auvynet C, Rosenstein Y. Multifunctional host defense peptides: Antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J 2009; Oct 9 DOI:10.1111/j.1742-4658.2009.07360.x.